Bliss Bio Health
Bliss Bio develops tumor-targeting biopharmaceuticals and antibody-drug conjugates (ADCs) to address unmet clinical needs in cancer treatment. The company focuses on creating differentiated biologic therapies through a combination of in-house research and strategic collaborations, aiming to improve patient outcomes in various tumor indications.
- Biotechnology
Funding
Founders
Founder details are not available yet.
Product
Problem
Many cancer treatments lack specificity, leading to systemic toxicity and reduced efficacy. There remains a significant unmet need for targeted therapies that selectively eliminate tumor cells while sparing healthy tissue.
Solution
BlissBio is a clinical-stage biotechnology company focused on developing innovative tumor-targeting antibody-drug conjugates (ADCs) and biopharmaceuticals for oncology. The company leverages its proprietary technology platforms and GMP-certified manufacturing facility to create differentiated biologic therapies. BlissBio's pipeline includes multiple ADCs in Phase I and Phase II clinical trials, targeting a variety of oncology indications. Through internal research and strategic collaborations, BlissBio aims to improve patient outcomes by delivering potent cytotoxic payloads directly to cancer cells, minimizing off-target effects.
Target Audience
The primary target audience includes patients with various types of cancer, as well as oncologists and other healthcare professionals involved in cancer treatment.
Features
- Proprietary ADC technology platforms for site-specific drug conjugation and optimized linker design
- GMP-certified manufacturing facility for in-house production of antibodies and ADCs
- Pipeline of tumor-targeting ADCs in Phase I and Phase II clinical trials
- Focus on oncology indications with unmet clinical needs
- Strategic collaborations to accelerate the development and commercialization of innovative biotherapeutics